ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
22.05 USD   +1.61%
05/20SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/20SECTOR UPDATE : Health Care
MT
05/20Anika Therapeutics Says FDA Approves X-Twist System for Soft Tissue Repair
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a joint preservation company that creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. The Company is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

Number of employees : 297 people.
Sales per Business
20202021Delta
Ostoarthritis Pain Management83.0363.6%89.5060.6% +7.8%
Joint Preservation and Restoration39.3730.2%48.5932.9% +23.42%
Non-orthopedic8.066.2%9.706.6% +20.38%
USD in Million
Sales per region
20202021Delta
United States103.1879.1%113.8377% +10.32%
Europe14.1810.9%19.5813.2% +38.09%
Other13.1010%14.389.7% +9.81%
USD in Million
Managers
Name Title Age Since
Cheryl Blanchard President, Chief Executive Officer & Director 56 2020
Michael L. Levitz Chief Financial Officer, Treasurer & EVP 47 2020
Mira Leiwant VP-Quality, Regulatory & Clinical Affairs - 2019
Steven W. Ek Vice President-Research & Development - 2020
Anne Nunes Vice President-Operations - 2021
Mark J. Namaroff Executive Director-IR & Corporate Communications 57 -
David Colleran Secretary, Executive VP & General Counsel 49 2020
James Chase Senior VP-International Sales & Marketing - 2018
Lisa Funiciello Vice President-Human Resources - 2022
Ian McLeod Chief Accounting Officer & Vice President - 2021
Members of the board
Name Title Age Since
Jeffery S. Thompson Chairman 55 2020
Raymond J. Land Independent Director 76 2006
Glenn R. Larsen, Dr. Independent Director 67 2015
Susan L. N. Vogt Independent Director 67 2018
John B. Henneman Independent Director 59 2020
Stephen O. Richard Independent Director 58 2020
Sheryl L. Conley Independent Director 60 2021
Cheryl Blanchard President, Chief Executive Officer & Director 56 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,543,860 14,288,359 98.2% 0 0.0% 98.2%
Shareholders
NameEquities%
Federated Investment Management Co. 1,562,600 10.8%
Kayne Anderson Rudnick Investment Management LLC 1,412,259 9.76%
The Vanguard Group, Inc. 966,145 6.68%
Trigran Investments, Inc. 954,799 6.60%
SSgA Funds Management, Inc. 929,498 6.42%
Dimensional Fund Advisors LP 870,299 6.02%
Columbia Wanger Asset Management LLC 766,289 5.30%
Avidity Partners Management LP 731,000 5.05%
Janus Henderson Investors US LLC 681,877 4.71%
Renaissance Technologies LLC 676,217 4.67%
Company contact information
Anika Therapeutics, Inc.
32 Wiggins Avenue
Bedford, MA 01730

Phone : +1.781.457.9000
Fax : +1.781.305.9720
Web : http://www.anikatherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Anika Therapeutics, Inc.